Randomized, Double-blind, Placebo-controlled Phase Ib/IIa Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment-naïve Patients and Treated Patients With Chronic Hepatitis B
This is a randomized, double-blind Phase Ib/IIa multicenter trial. All eligible subjects will receive TQA3605 tablets or placebo in combination with nucleoside (acid) analogues. A total of 64 subjects will be enrolled.
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Entecavir 1 mg tablets relative to Baraclude 1 mg tablets in healthy Thai volunteers under fasting condition
开始日期2023-08-08
申办/合作机构-
100 项与 HBV逆转录酶 相关的临床结果
登录后查看更多信息
100 项与 HBV逆转录酶 相关的转化医学
登录后查看更多信息
0 项与 HBV逆转录酶 相关的专利(医药)
登录后查看更多信息
62
项与 HBV逆转录酶 相关的文献(医药)
2022-11-08·Viruses
Ivermectin Inhibits HBV Entry into the Nucleus by Suppressing KPNA2.